Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Gracell Biotechnologies

Company Type: Therapeutic development

Main focus: Advancing autologous and allogeneic CAR-T cell therapies to treat various cancers and autoimmune diseases

Company stage: Clinical

Diseases: Haematological and solid cancers, Systemic Lupus Erythematosus

Genome-editing tool: CRISPR-Cas9

Funding stage: Post-IPO Equity

Location: Suzhou, Jiangsu, China

Website: www.gracellbio.com

Pipeline: www.gracellbio.com/pipeline/

Partners:

Gracell Biotechnologies is a global clinical-stage biopharmaceutical company dedicated to discovering and developing innovative cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich pipeline of autologous and allogeneic product candidates designed to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality and a lack of effective CAR-T therapies for solid tumours and autoimmune diseases.

Gracell Biotechnologies Co., Ltd

Press Releases

Related News and Updates

Job Opportunities

Clinical Trials

Pre-clinical Trials

Stocks and Markets

Diseases

Webinar

Your Latest CMN News

CMN Weekly (21 February 2025) - Your Weekly CRISPR...

CMN Weekly

Feb. 21, 2025

Some of the best links we picked up around the internet

Bahrain Reports First Administration of CASGEVY in...

Feb. 19, 2025

The Bahrain Oncology Centre announced a major milestone on Sunday with the successful administration of CASGEVY - the world's only approved therapy...

CRISPR–Csm enables single-molecule RNA imaging in...

CMN Briefs

Feb. 18, 2025

A new technique developed by Jennifer Doudna and colleagues at the University of California, Berkeley, achieves single-molecule resolution imaging of...

CRISPR screen links BAF mutation to premature...

CMN Briefs

Feb. 17, 2025

A genome-wide CRISPR screen in fibroblasts from patients with Néstor-Guillermo Progeria Syndrome (NGPS) identified 43 genes that mitigate multiple...

CMN Weekly (14 February 2025) - Your Weekly CRISPR...

CMN Weekly

Feb. 14, 2025

Some of the best links we picked up around the internet

FDA Grants Dual Designations to Arbor's Gene...

CMN Clinical

Feb. 12, 2025

The FDA has granted orphan drug and rare pediatric disease designations to Arbor Biotechnologies' ABO-101, a gene-editing therapeutic candidate for...